Table 1.
Baseline Characteristics of patients receiving intensive treatment.
| Characteristics | Total N = 75 | Group 1 ( > Q8W) N = 33 | Group 2 ( < Q8W) N = 42 |
|---|---|---|---|
|
Age Mean ± SD (years) |
84.35 ± 7.5 | 85.70 ± 6.3 | 83.29 ± 8.3 |
| Gender | ♂ 46 | ||
| ♂ n (%) | (61.3%) | ♂ 25 (75.8%) | ♂ 21 (50%) |
| ♀ n (%) | ♀ 29 (38.7%) | ♀ 8 (24.2%) | ♀ 21 (50%) |
| Pseudophakic | |||
| n (%) | 64 (85.3%) | 31 (93.9%) | 33 (78.6%) |
| Vitrectomy | |||
| n (%) | 5 (6.7%) | 3 (9.1%) | 2 (4.8%) |
| CNV type n (%) | |||
| 1 | 48 (64%) | 15 (45.5%) | 33 (78.6%) |
| 2 | 22 (29.3%) | 15 (45.5%) | 7 (16.7%) |
| 3 | 5 (6.7%) | 3 (9.1%) | 2 (4.8%) |
|
Mean max dosing interval (weeks) |
10.17 ± 3.9 | 13.73 ± 3.2 | 7.38 ± 1.2 |
| ERM n (%) | 20 (26.7%) | 11 (33.3%) | 9 (21.4%) |
| Time to achieve a Q8W interval (months) | 59.2 ± 37.15 | 59.2 ± 37.15 | N/A |
| Macular hematoma n (%) | 8 (10.7%) | 3 (9.1%) | 5 (11.9%) |
| Injection frequency (number of injections/week) | 6.57 ± 1.6 | 7.71 ± 1.8 | 5.68 ± 0.8 |
| Follow-up duration | |||
| Mean ± SD (years) | 5.63 ± 3.6 | 7.44 ± 3.3 | 4.21 ± 3.1 |
| Median (years) | 4.40 | 7.04 | 3.17 |
| CNV surface area | |||
| μm2 | 4.13 ± 4.9 | 4.29 ± 5.5 | 4.01 ± 4.4 |
| Number of intravitreal injections | |||
| Mean ± SD | 41.8 ± 26.7 | 48.82 ± 24.7 | 36.29 ± 27.2 |
| Ranibizumab | |||
| loading dose n (%) | 51 (68%) | 22 (66.6%) | 29 (69%) |
| Last follow-up visit n (%) | 14 (18.6%) | 6 (18.1%) | 8 (19%) |
| Aflibercept | 24 (32%) | 11 (33.4%) | 13 (31%) |
| loading dose n (%) | 61 (81.4%) | 27 (81.9%) | 34 (81%) |
Note all six patients demonstrating stereopsis at 10½ years also demonstrated stereopsis with the Frisby and Titmus tests at age 4½ years.